教程說明案例_第1頁
教程說明案例_第2頁
教程說明案例_第3頁
教程說明案例_第4頁
教程說明案例_第5頁
免費(fèi)預(yù)覽已結(jié)束,剩余34頁可下載查看

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)

文檔簡介

肝癌立體定向放療(SBRT)進(jìn) StrategyfortreatmentassignmentinpatientswithHCCaccordingtotheproposalfromtheBCLCstagingsystemTarget:OS:20

Target:OS:11

Target:OS:<3AASLD,ESMO,andEASL,etal.Managementofhepatocellular2SequentialPhaseIandIITrialsSBRTforLocallyAdvanced-------(StudyofPrincessMargaret patientswithHCCunsuitableforOP,RFA,TACEChild-Turcotte-PughclassAdisease,≥700mLof -HCCliver.TheSBRTdoserangewas24to54Gyinsixfractions.AlexisBujold,LauraA.DawsonTreatment +5mm(8mmTrail-CTV2includeliverparenchyma,RFAcavities,orpost-TACEvolumesadjacentto Contrast-enhancingTVTwasincludedasCTV1, enhancingthrombosiswasgenerallyincludedPTVmarginsof5mmweretailoredfromthepatient’sbreathingmotionandmotionCRTwith5-10 coplanarbeamsof6to18MV.(IMRTwerePTV1:30to54Gy(24to54GyinTrial1)/6f,3F/Week,TVTplusPTVmargin:30GyifOARConstrainDosetoPTV1wasdeterminedaccordingtoanRILDnormaltissuecomplicationprobabilitymodelbasedontheeffectiveirradiatedlivervolumeStrictdoseconstraintsweremaintainedforthesurroundingorgansatinapopulationofpatientsforwhomcurativelocaltreatmentoptionsarenotavailable,SBRTcanleadtosustainedlocalcontrol,associatedwithsurvivalrateshigherthanhistoricalcontrols,withalowriskofserioustoxicity.DiseaseprogressionoutsidethetargetedHCCremainsaproblem,providingrationaleforcombiningSBRTwithregionalorsystemictherapies.(RTOG1112).----phaseIIIrandomizedtrialforlocallyadvancedHCCSorafenibVSSorafenib+SBRTKCCHKCCHStudy:SBRTforHCCasaLocalSalvageTreatment pletePhase2trialofSBRTasalocalsalvagetreatment TACEinpatientswithfocusedontumorresponseandLCage>18 ECOG:0-InitialdiagnosisofprimaryHCCorinoperableorrefusalunsuitabilityforRFAorWBC>2000/lL,Hb>8.0g/dL,PLT>50,000/lL,absoluteneutrophilcount≥1500/lL,ASTandALT<5times;bilirubin3.0mg/Dl,ChPAorB;pleteresponseafterTACEafter1to5asinglelesionormultiplelesions,includingportalveintumorDimenter<10noevidenceofanuncontrolledlesionatanyotherPTV=ITV+4mm(S-I),2mm(L-R,A-BreathControl:compresstheMi-SookKim,Cancer thecurrenttrialdemonstratesthatSBRTafter pleteTACEforinoperableHCCachievespromisingresponseandLCrates.However,alongerfollow-upwillberequiredtoconfirmthisfinding.Onthebasisoftheresultsfromthisstudy,weareplanninganewmulti-institutionalphase2trialtoreduceGItoxicitiesand CaseCasefromTianjinCancerPET-

6monthsafter6monthsafterPET-16monthsafterTheThecaseofpatientreceivingTACEplusCase1: Case2:OurunpublishedpatientCyberknifehascurativeeffectforHCCStageIStageICyberknifeVSOperatingInclusionInclusionpathologicaldiagnosisofhepatocellularcarcinoma(HCC)StageI(AJCC7R0resectionforsurgicalRadicalradiotherapyforcyberknife49223leftlobeRightlobecaudatelobeTumordiametersFollowingToxicity(CTC3.0≧2 IntestinalstenosisIntestinalfistula

LocalLocalefficacyofRecenteffect LocalcontrolAFPAFP1-2mafter3-6mafter1-2mafter3-6mafterHistogramof ComparisonComparisonofPFS/OSbetweencyberknifeandsurgeryCauseof CasesofCauseofTumor-8-tumor-*PTumorTumorspecial ThisstudyhasmadeapreliminaryexplorationintheselectionofnewtreatmentsforStageIhepatocellularcarcinomaandaninvestigationontheefficacyofCyberKnifetreatment.CyberKnifetreatmentforStageIhepatocellularcarcinomaisequivalenttothatofsurgicalexcision,withmilderadverseevents.LargeLargetumor,closetotheGIandInoperable,notfeasible,orCCRT-CCRT-SBRTSBRTTACE+PalliativeJiangW,etal.Oncology2013;84(S1):69-

LeeIJ,etal.GutandLiver2012;6:139-EligibilitycriteriafordifferenttreatmentNaokoSanuki,WorldJGastroenterol2014;20(12):3100-TypicalliverlocationssuitforProspectivestudiesofSBRTforRetrospectivestudiesofSBRTforSBRTforHCCshowthecurativepotentialforthelocaldisease.SBRTfor )-coplanarRadiationusually8-12 accordingtothedifferentSizeandcontrolofIGRTtoimproveset-upaccuracyandtreatmentThemostcommonsiteoffirstrecurrencewasthelivertheirradiatedvolume(RTOG-majorSBRT-inducedcomplicationsincludeRILD

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論